| Project/Area Number |
20590494
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Immunology
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
KAZUYOSHI Takeda Juntendo University, 医学部, 准教授 (80272821)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKANO Hiroyasu 順天堂大学, 医学部, 准教授 (70276476)
AKIBA Hisaya 順天堂大学, 医学部, 准教授 (60338316)
NAKAYAMA Katsufumi 順天堂大学, 医学部, 助教 (20453582)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NAKANO Hiroyasu 順天堂大学, 医学部, 准教授 (70276476)
AKIBA Hisaya 順天堂大学, 医学部, 准教授 (60338316)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 免疫監視 / 腫瘍免疫 / 癌治療 / 細胞死 / 免疫活性化 / 免疫抑制 / regulatory T細胞 / 所属リンパ節 / CTL / CTLA-4 / アポトーシス / Tim-3 / CD8α^+樹状細胞 / トレランス / C-ERC / mesotheli / ADCC / 中皮腫 / NK細胞 / TRAIL / DR5 / CD40 / CD137 / IL-15 / Erb-2 / HER2 / histone deacetylase inhibitor / bortezomib |
|---|
| Research Abstract |
TrimAb is the antibody cocktail therapy combining tumor apoptosis-inducing therapy with immune-activating therapy. We have here found that trimAb synergistically eradicated tumors when combined with several kinds of anti-tumor molecular targeting reagents that were already applied to clinical treatment. Suppression of immune inhibitory responses due to phagocytosis of apoptotic tumor cells is possibly useful to augment immune therapies against cancers. Moreover, based on the results of combination with several therapies targeting immune inhibition, we revealed that improvement of immune environment in tumor mass is the most critical to augment specific anti-tumor immune responses inducing tumor rejection.
|
